Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports that ZD1839 (Iressa), an anticancer drug, was associated with acneiform eruptions and hair growth abnormalities due to its inhibition of epidermal growth factor receptor signaling in the skin.

This study reports that Iressa, an anti-cancer agent, commonly causes acneiform eruptions and xerosis as cutaneous side effects, similar to other agents targeting epidermal growth factor receptors.

This study suggests that hair loss disorders like Marie Unna hereditary hypotrichosis may result from mutations that disrupt post-transcriptional regulation of HR protein expression by PCPB2 interacting with Hr mRNA.

In a reported case, the use of ZD1839 (Iressa), an EGFR tyrosine kinase inhibitor, resulted in hair changes and acneiform eruptions as cutaneous side effects.

This research observed that translation initiation shifts from cap-dependent to IRES-mediated pathways varied across tissues and cell types under stress and differentiation conditions in mice, with low IRES/Cap ratios signaling high stemness and potential multipotency, mediated by the RNA processing protein PTBP1.